These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 31416465)
1. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Ito T; Thachil J; Asakura H; Levy JH; Iba T Crit Care; 2019 Aug; 23(1):280. PubMed ID: 31416465 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365 [TBL] [Abstract][Full Text] [Related]
3. Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis. Yamakawa K; Murao S; Aihara M Thromb Haemost; 2019 Jan; 119(1):56-65. PubMed ID: 30597500 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687 [TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. Iba T; Gando S; Thachil J J Thromb Haemost; 2014 Jul; 12(7):1010-9. PubMed ID: 24801203 [TBL] [Abstract][Full Text] [Related]
6. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients. Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K; Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis. Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388 [TBL] [Abstract][Full Text] [Related]
10. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T Crit Care; 2011; 15(3):R123. PubMed ID: 21569368 [TBL] [Abstract][Full Text] [Related]
11. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study. Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004 [TBL] [Abstract][Full Text] [Related]
12. Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation. Iba T; Helms J; Totoki T; Levy JH Semin Thromb Hemost; 2024 Oct; 50(7):1012-1018. PubMed ID: 38733977 [TBL] [Abstract][Full Text] [Related]
13. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial. Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291 [TBL] [Abstract][Full Text] [Related]
14. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation. Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566 [TBL] [Abstract][Full Text] [Related]
15. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Yamato M; Minematsu Y; Fujii J; Mori K; Minato T; Miyagawa S; Fujimura R; Morikage N; Arata Y; Nakano C; Wada A; Ito T Ther Apher Dial; 2013 Oct; 17(5):472-6. PubMed ID: 24107274 [TBL] [Abstract][Full Text] [Related]
16. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Iba T; Thachil J Int J Hematol; 2016 Mar; 103(3):253-61. PubMed ID: 26588929 [TBL] [Abstract][Full Text] [Related]
17. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Iba T; Nagaoka I; Boulat M Thromb Res; 2013 May; 131(5):383-9. PubMed ID: 23566533 [TBL] [Abstract][Full Text] [Related]